[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362928-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-362928-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","persevere-persevere-longitudinal-assessment-of-quality-of-life-and-treatment-toxicities-in-chinese-breast-cancer-patients-a-multicentre-cohort-study-protocol","PERSEVERE - PERSEVERE longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients - a multicentre cohort study protocol","","PERSEVERE is a prospective, multicentre observational cohort study assessing longitudinal quality of life (QoL) and treatment-related toxicities in Chinese women with stage I–III invasive breast cancer. Approximately 3000 newly diagnosed participants will be enrolled across cancer centres in China, with data collected at baseline and serial follow-ups for up to 5 years using validated patient-reported outcome measures via a centralised REDCap platform. The primary endpoint is change in EORTC QLQ-C30 global health status/QoL score from baseline to 12 months, supported by longitudinal and time-to-event analyses.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/persevere-persevere-longitudinal-assessment-of-quality-of-life-and-treatment-toxicities-in-chinese-breast-cancer-patients-a-multicentre-cohort-study-protocol/362928/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/persevere-persevere-longitudinal-assessment-of-quality-of-life-and-treatment-toxicities-in-chinese-breast-cancer-patients-a-multicentre-cohort-study-protocol/362928.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the PERSEVERE study?","Question",{"text":63,"@type":64},"To characterise longitudinal trajectories of quality of life and treatment-related toxicities among Chinese women with stage I–III breast cancer and to identify factors linked to suboptimal recovery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many participants and what study setting are involved?",{"text":68,"@type":64},"Approximately 3000 women with newly diagnosed stage I–III invasive breast cancer will be enrolled across multiple cancer centres in China.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the primary outcome of the study?",{"text":72,"@type":64},"The primary outcome is the change in the EORTC QLQ-C30 global health status/QoL score from baseline to 12 months.",{"name":74,"@type":61,"acceptedAnswer":75},"What are key strengths and limitations noted?",{"text":76,"@type":64},"Strengths include large-scale, predefined multicentre prospective design, comprehensive multimodal data collection, and digital infrastructure. Limitations include limited generalisability beyond a Chinese population and potential residual confounding affecting causal inference.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},362928,1790190292,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Protocol  \n PERSEVERE: longitudinal assessment  \nof quality of life and treatment toxicities in Chinese breast cancer patients – amulticentre cohort study protocol  \nZheng Qu  ,1 Haijun Wang,2 Qi Li,1 Yuxuan Zhang,3 Kexin Li,4 Shengbin Pei,1 Yazhe Yang,1 Luxiao Zhang,1 Xue Yang,1 Jing Wang,1 Yi Fang1  \nTo cite: Qu Z, Wang H, Li Q, et al. PERSEVERE: longitudinal assessment of quality of  \nlife and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol. BMJ Open 2026;16:e115797 . doi:10 . 1136/ bmjopen-2025-115797  \n► Prepublication history for this paper is available online. To view these files, please visit the journal online ([https://doi](https://doi). org/10 . 1136/bmjopen-2025- 115797) .  \nZQ, HW and QL contributed equally.  \nXY, JW and YF contributed equally.  \nReceived 22 December 2025 Accepted 06 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Xue Yang;  \nyoyoyang1[16@sina.com](16@sina.com), Dr Jing Wang; [wangjing@cicams.ac.cn](wangjing@cicams.ac.cn) and Dr Yi Fang; [fangyi@cicams.ac.cn](fangyi@cicams.ac.cn)  \nABSTRACT  \nIntroduction Survival outcomes for early-stage breast cancer have improved substantially; however, many survivors experience persistent treatment-related toxicities that adversely affect long-term quality of life (QoL) and functional recovery. Prospective survivorship data from China remain limited. The PERSEVERE study aims to characterise longitudinal trajectories of QoLand treatment-related toxicities among Chinese women treated for stage I–III breast cancer and to identify factors associated with suboptimal recovery.  \nMethods and analysis PERSEVERE is a prospective, multicentre, observational cohort study enrolling approximately 3000 women with newly diagnosed stage I–III invasive breast cancer across cancer centres in China. Data are collected at baseline and serially for up to 5 years, including clinical variables, a validated suite of patient-reported outcome measures collected via a centralised REDCap electronic platform and baseline biospecimens. The primary outcome is the change in the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 global health status/QoL score from baseline to 12 months. Longitudinal and time-toevent analytical approaches appropriate for observational cohort studies will be applied, with exploratory analyses planned to investigate symptom trajectories and biological correlates.  \nEthics and dissemination The study protocol (ID: NCC25/629-5575) has been approved by the Independent Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences. Written informed consent will be obtained from all participants. Study findings will be disseminated through peer-reviewed open-access publications and presentations at national and international conferences, with summaries shared with clinicians and patient advocacy groups.  \nTrial registration number NCT07010939.  \nINTRODUCTION  \nBreast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. In 2022, an estimated 2.3 million new cases and 670 000 deaths were reported globally, with incidence and mortality projected to  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This is a large-scale, multicentre prospective cohort study with a predefined protocol designed to longitudinally assess quality of life and treatment-related toxicity among patients with stage I–III breast cancer in China.  \n⇒ The study incorporates a comprehensive multimodal data collection framework, integrating standardised clinical data, validated patient-reported outcome measures and a centralised biobank to support future translational analyses.  \n⇒ Longitudinal data quality is strengthened through the use o","cbCaianFGN8hk5a5","https://ap.wps.com/l/cbCaianFGN8hk5a5","pdf",261812,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Ethics and dissemination\n# Strengths and limitations of this study","[{\"question\":\"What is the main purpose of the PERSEVERE study?\",\"answer\":\"To characterise longitudinal trajectories of quality of life and treatment-related toxicities among Chinese women with stage I–III breast cancer and to identify factors linked to suboptimal recovery.\"},{\"question\":\"How many participants and what study setting are involved?\",\"answer\":\"Approximately 3000 women with newly diagnosed stage I–III invasive breast cancer will be enrolled across multiple cancer centres in China.\"},{\"question\":\"What is the primary outcome of the study?\",\"answer\":\"The primary outcome is the change in the EORTC QLQ-C30 global health status/QoL score from baseline to 12 months.\"},{\"question\":\"What are key strengths and limitations noted?\",\"answer\":\"Strengths include large-scale, predefined multicentre prospective design, comprehensive multimodal data collection, and digital infrastructure. Limitations include limited generalisability beyond a Chinese population and potential residual confounding affecting causal inference.\"}]","PERSEVERE - PERSEVERE longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients - a multicentre cohort study protocol | PDF",1790149443,23,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/972ffe7b8675fc7acfba1f9eeaa440c2.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55e8b03cf18daa214a22aa291cd6d6bf.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4b35283129e3c540fb84153238f9590.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b98e3a16da17177efe875659223613d2.webp",980,1306]